Mackenzie Financial Corp Buys 119 Shares of argenx SE (NASDAQ:ARGX)

Mackenzie Financial Corp boosted its stake in shares of argenx SE (NASDAQ:ARGX) by 6.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,863 shares of the company’s stock after buying an additional 119 shares during the quarter. Mackenzie Financial Corp’s holdings in argenx were worth $709,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ARGX. CWM LLC lifted its holdings in argenx by 29.4% during the 3rd quarter. CWM LLC now owns 207 shares of the company’s stock valued at $102,000 after buying an additional 47 shares in the last quarter. DAVENPORT & Co LLC lifted its holdings in argenx by 11.8% during the 3rd quarter. DAVENPORT & Co LLC now owns 1,407 shares of the company’s stock valued at $692,000 after buying an additional 148 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in argenx by 5.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 27,466 shares of the company’s stock valued at $13,503,000 after buying an additional 1,364 shares in the last quarter. Raymond James & Associates lifted its holdings in argenx by 132.3% during the 3rd quarter. Raymond James & Associates now owns 33,771 shares of the company’s stock valued at $16,603,000 after buying an additional 19,232 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its holdings in argenx by 15.8% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 11,096 shares of the company’s stock valued at $5,455,000 after buying an additional 1,518 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

ARGX has been the subject of several recent research reports. JMP Securities restated a “market outperform” rating and issued a $471.00 price target on shares of argenx in a report on Friday, March 22nd. Wedbush restated an “outperform” rating and issued a $521.00 price target on shares of argenx in a report on Thursday, April 18th. Scotiabank boosted their price target on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a report on Tuesday, March 26th. Truist Financial boosted their price target on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Finally, Wolfe Research initiated coverage on shares of argenx in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and an average price target of $528.16.

argenx Stock Down 1.7 %

Shares of argenx stock opened at $368.60 on Friday. The company has a market cap of $21.91 billion, a P/E ratio of -71.71 and a beta of 0.65. argenx SE has a 52-week low of $327.73 and a 52-week high of $550.76. The firm’s 50 day moving average price is $386.41 and its 200-day moving average price is $418.17.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million for the quarter, compared to analysts’ expectations of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same period in the prior year, the firm posted ($0.70) EPS. As a group, equities research analysts forecast that argenx SE will post -2.1 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.